Celgene Corp. (NASDAQ: CELG) owns ex-U.S. rights to Juno Therapeutics' (NASDAQ: JUNO) lead drug, liso-cel (formerly JCAR017), and it owns nearly 10% of Juno Therapeutics' stock, yet that may not be enough to satisfy Celgene's desire …
CEL-SCI Corporation (NYSE: CVM), a late-stage oncology company, today announced that it intends to offer and sell common stock and warrants, subject to market and other conditions, in an underwritten public offering. The shares and …
CEL-SCI Corporation ( CVM) was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the …
Cel-Sci - entered definitive agreement with one institutional investor for offering of shares of stock with proceeds of about $1.51 million in direct offering * Cel-Sci corp- intends to use net proceeds from offering for phase 3 clinical study and …
he was late in reporting sales of 2,324,222 shares of Cel-Sci stock totaling more than $2.6 million. The SEC said the reports were 2 to 31 weeks late. Similarly, the SEC`s action against Genesis Investment Corp. alleged that between …
Or maybe I run out of petrol like that because I’ll be beating every Skyline, Supra, basically any car in a race, with my fully sick, decked out stock engine ... s just random codes that pop up when the CEL comes on. With Lexus being a luxury …
CEL is listed on the Hong Kong Stock Exchange. If the deal gets regulatory and shareholder approvals, CEL will become the second largest shareholder of Ying Li after the share subscription, ranking next to Mr Fang Ming, the executive …
Cellcom Israel Ltd. (NYSE CEL) (the "Company") announced today ... http://www.prnewswire.com/news-releases/cellcom-israel-announces-results-of-extraordinary-general-meeting-of-shareholders-300470901.html